# Haemonetics (HAE) — News

HAE · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/hae/news

## Recent headlines

- [Haemonetics Corp: Barrington Research raises target price to $140 from $118](https://www.ainvest.com/news/haemonetics-corp-barrington-research-raises-target-price-140-118-2610) — AInvest Wire, Oct 9, 2026
  Barrington Research has revised its price target for Haemonetics Corp, raising it to $140 from $118, reflecting a positive reassessment of the company’s outlook. The adjustment indicates increased confidence in Haemonetics’ financial performance and strategic direction. Investors are advised to…
- [Haemonetics Corp: Mizuho raises target price to $140 from $95](https://www.ainvest.com/news/haemonetics-corp-mizuho-raises-target-price-140-95-2610) — AInvest Wire, Oct 9, 2026
- [Haemonetics shares jump 12.5% after supply agreement with CSL Plasma](https://www.ainvest.com/news/haemonetics-shares-jump-12-5-supply-agreement-csl-plasma-2610) — AInvest Wire, Oct 8, 2026
  Haemonetics Corp (NYSE:HAE) shares rose 16.01% to $104.72 as of Tuesday afternoon, reaching a new 52-week high, following the announcement of a supply agreement with CSL . The agreement allows CSL Plasma to use Haemonetics’ NexSys PCS devices with Persona PLUS technology across its U.S. collection…
- [Haemonetics Corp: BTIG raises target price to $130 from $110](https://www.ainvest.com/news/haemonetics-corp-btig-raises-target-price-130-110-2610) — AInvest Wire, Oct 8, 2026
  BTIG, a financial services firm, has raised its price target for Haemonetics Corporation (HAE) to $130 per share from $110, reflecting a positive outlook on the company’s performance and potential growth. The updated target indicates increased confidence in Haemonetics’ business trajectory, though…
- [Csl - To complete Haemonetics platform rollout in U.S. plasma centres by end 2027](https://www.ainvest.com/news/csl-complete-haemonetics-platform-rollout-plasma-centres-2027-2610) — AInvest Wire, Oct 8, 2026
  Haemonetics Corporation has announced plans to complete the rollout of its integrated platform across U.S. plasma centers by the end of 2027, as part of its broader strategy to enhance operational efficiency and market competitiveness. The company’s recent first-quarter fiscal 2027 earnings call…

## Similar Stocks

- [PODD](https://www.lighthorse.io/tickers/podd) — Insulet Corporation - Common Stock
- [DXCM](https://www.lighthorse.io/tickers/dxcm) — DexCom, Inc. - Common Stock
- [QTRX](https://www.lighthorse.io/tickers/qtrx) — Quanterix Corporation - Common Stock
- [SIBN](https://www.lighthorse.io/tickers/sibn) — SI-BONE, Inc. - Common Stock
- [PEN](https://www.lighthorse.io/tickers/pen) — Penumbra, Inc. Common Stock
- [ZBH](https://www.lighthorse.io/tickers/zbh) — Zimmer Biomet Holdings, Inc. Common Stock
- [HQY](https://www.lighthorse.io/tickers/hqy) — HealthEquity, Inc. - Common Stock
- [LNTH](https://www.lighthorse.io/tickers/lnth) — Lantheus Holdings, Inc. - Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).